Showing 1621-1630 of 7113 results for "".
Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Achieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisFDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.DermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, tHair Today
https://practicaldermatology.com/conferences/scale-2023/hair-today/20204/Joel L. Cohen, MD, and Doris Day, MD, discuss the latest advances in treating hair loss including the use of lasers with topicals, supplements, or PRP injections. They also discuss some of the risks associated with the use of biotin as a hair growth supplement.Recognizing Dermatologic Emergencies in Kids
https://practicaldermatology.com/conferences/scale-2023/recognizing-dermatologic-emergencies-in-kids/20198/Infections including congenital infections, syphilis, or HSV are the No. 1 cause of pediatric skin emergencies. Infantile hemangiomas in the airway can affect breathing and also require fast and early treatment, explains Thy Huynh, MD.Clinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts diDermWireTV: USPSTF Tackles Racism; Winlevi Launch; Derm Days in Focus
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-uspstf-tackles-racism-winlevi-launch-derm-days-in-focus/20014/The US Preventive Services Task Force is undertaking efforts to mitigate the influence of systemic racism in its recommendations. Global Psoriasis Day, National Biologics Coordinators Day, and Retinol Day bring attention to skin issues. Sun Pharmaceutical’s Winlevi (clascoterone) cream 1% is now avaStay Relevant with Education
https://practicaldermatology.com/series/dermatology-education-foundation/stay-relevant-with-education/19989/Feed yourself new information and stay on top of data regarding new and existing medications in order to offer patients the best care possible, says Wendy Cantrell, CRNP, DNP. This is particularly important as new understanding of conditions like psoriasis and atopic dermatitis evolve and new treatm